Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital; Broad Institute of MIT and Harvard.
Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital; Broad Institute of MIT and Harvard; Department of Medicine, Harvard Medical School;
J Vis Exp. 2024 Aug 16(210). doi: 10.3791/66766.
Human tumor samples hold a plethora of information about their microenvironment and immune repertoire. Effective dissociation of human tissue samples into viable cell suspensions is a required input for the single-cell RNA sequencing (scRNAseq) pipeline. Unlike bulk RNA sequencing approaches, scRNAseq enables us to infer the transcriptional heterogeneity in tumor specimens at the single-cell level. Incorporating this approach in recent years has led to many discoveries, such as identifying immune and tumor cellular states and programs associated with clinical responses to immunotherapies and other types of treatments. Moreover, single-cell technologies applied to dissociated tissues can be used to identify accessible chromatin regions T and B cell receptor repertoire, and the expression of proteins, using DNA barcoded antibodies (CITEseq). The viability and quality of the dissociated sample are critical variables when using these technologies, as these can dramatically affect the cross-contamination of single cells with ambient RNA, the quality of the data, and interpretation. Moreover, long dissociation protocols can lead to the elimination of sensitive cell populations and the upregulation of a stress response gene signature. To overcome these limitations, we devised a rapid universal dissociation protocol, which has been validated on multiple types of human and murine tumors. The process begins with mechanical and enzymatic dissociation, followed by filtration, red blood lysis, and live dead enrichment, suitable for samples with a low input of cells (e.g., needle core biopsies). This protocol ensures a clean and viable single-cell suspension paramount to the successful generation of Gel Bead-In Emulsions (GEMs), barcoding, and sequencing.
人类肿瘤样本包含大量有关其微环境和免疫组成的信息。有效地将人体组织样本解离成有活力的细胞悬浮液是单细胞 RNA 测序 (scRNAseq) 流程的必需输入。与批量 RNA 测序方法不同,scRNAseq 使我们能够在单细胞水平上推断肿瘤标本中的转录异质性。近年来,将这种方法纳入研究中已经带来了许多发现,例如鉴定与免疫疗法和其他类型治疗的临床反应相关的免疫和肿瘤细胞状态和程序。此外,应用于解离组织的单细胞技术可用于识别可及染色质区域 T 和 B 细胞受体库,以及使用 DNA 条形码抗体 (CITEseq) 表达蛋白质。在使用这些技术时,解离样本的活力和质量是关键变量,因为这些变量会极大地影响单个细胞与环境 RNA 的交叉污染、数据质量和解释。此外,长时间的解离方案可能会导致敏感细胞群的消除和应激反应基因特征的上调。为了克服这些限制,我们设计了一种快速通用的解离方案,该方案已在多种类型的人类和鼠类肿瘤上得到验证。该过程从机械和酶解开始,然后进行过滤、红细胞裂解和死活细胞富集,适用于细胞输入量低的样本(例如,针芯活检)。该方案确保了干净且有活力的单细胞悬浮液是成功生成凝胶珠乳液 (GEMs)、条形码和测序的关键。